DE602006020563D1 - Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene-heterokomplexe aus tnf-aplha und einem trägerprotein - Google Patents

Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene-heterokomplexe aus tnf-aplha und einem trägerprotein

Info

Publication number
DE602006020563D1
DE602006020563D1 DE602006020563T DE602006020563T DE602006020563D1 DE 602006020563 D1 DE602006020563 D1 DE 602006020563D1 DE 602006020563 T DE602006020563 T DE 602006020563T DE 602006020563 T DE602006020563 T DE 602006020563T DE 602006020563 D1 DE602006020563 D1 DE 602006020563D1
Authority
DE
Germany
Prior art keywords
carrier protein
aplha
antigene
tnf
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020563T
Other languages
English (en)
Inventor
Daniel Zagury
Buanec Helene Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neovacs SA
Original Assignee
Neovacs SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs SA filed Critical Neovacs SA
Publication of DE602006020563D1 publication Critical patent/DE602006020563D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE602006020563T 2005-05-24 2006-05-24 Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene-heterokomplexe aus tnf-aplha und einem trägerprotein Active DE602006020563D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05300404 2005-05-24
PCT/EP2006/005044 WO2007022813A2 (en) 2005-05-24 2006-05-24 A METHOD FOR PREPARING A STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES OF TNFα AND A CARRIER PROTEIN

Publications (1)

Publication Number Publication Date
DE602006020563D1 true DE602006020563D1 (de) 2011-04-21

Family

ID=35746986

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020563T Active DE602006020563D1 (de) 2005-05-24 2006-05-24 Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene-heterokomplexe aus tnf-aplha und einem trägerprotein

Country Status (13)

Country Link
US (1) US7887811B2 (de)
EP (1) EP1888122B1 (de)
JP (1) JP5061099B2 (de)
CN (1) CN101222941A (de)
AT (1) ATE500848T1 (de)
AU (1) AU2006284248B2 (de)
BR (1) BRPI0609932A2 (de)
CA (1) CA2609572C (de)
DE (1) DE602006020563D1 (de)
ES (1) ES2382229T3 (de)
NZ (1) NZ563526A (de)
WO (1) WO2007022813A2 (de)
ZA (1) ZA200710011B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2725035A1 (de) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antikörpertherapie zur Verwendung im Verdauungstrakt
CN107412754A (zh) * 2009-12-22 2017-12-01 塞尔德克斯医疗公司 疫苗组合物
EP2462950A1 (de) 2010-12-08 2012-06-13 Neovacs Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung
CA2820837A1 (en) * 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
CN103917555A (zh) * 2011-08-01 2014-07-09 艾瓦夏生物制剂公司 人tnf特异性的牛科动物多克隆抗体
WO2015017683A1 (en) * 2013-07-31 2015-02-05 Malast Mary Antimicrobial compositions and methods of use
US9733162B2 (en) 2014-02-11 2017-08-15 Ihor Turkevych Universal system, method and solution for the acceleration of the process of fixing, dehydrating and clearing the structure of biological tissue
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
CN115594770B (zh) * 2022-12-14 2023-04-07 上海惠盾因泰生物科技有限公司 一种针对人TNFα分子的类风湿关节炎治疗性疫苗的构建

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5578308A (en) * 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
FR2812813B1 (fr) 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
ITMI20010571A1 (it) * 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation

Also Published As

Publication number Publication date
BRPI0609932A2 (pt) 2011-10-11
CN101222941A (zh) 2008-07-16
JP5061099B2 (ja) 2012-10-31
ES2382229T3 (es) 2012-06-06
CA2609572A1 (en) 2007-03-01
CA2609572C (en) 2013-11-19
ATE500848T1 (de) 2011-03-15
US7887811B2 (en) 2011-02-15
AU2006284248A1 (en) 2007-03-01
US20080193473A1 (en) 2008-08-14
AU2006284248B2 (en) 2010-10-07
WO2007022813A3 (en) 2007-04-26
EP1888122A2 (de) 2008-02-20
JP2008542227A (ja) 2008-11-27
EP1888122B1 (de) 2011-03-09
NZ563526A (en) 2009-02-28
WO2007022813A2 (en) 2007-03-01
ZA200710011B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
DE602006020563D1 (de) Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene-heterokomplexe aus tnf-aplha und einem trägerprotein
DE60101681D1 (de) Verfahren zur herstellung kobalt-katalysatoren
WO2009010877A3 (en) Conjugate purification
DE502005001841D1 (de) Verfahren zur herstellung von 1,4-diphenylazetidinon-derivaten
DE502004009763D1 (de) Verfahren zur herstellung von 1-buten
DE60231486D1 (de) Verfahren zur herstellung eines wasserlöslichen behälters
ATE533019T1 (de) Verfahren zur herstellung eines pulverförmigen produkts
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
DE602006006654D1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
ATE444950T1 (de) Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
ATE486841T1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
DE602006013151D1 (de) Verfahren zur herstellung von polymermaleimiden
DE60234952D1 (de) VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
ATE430559T1 (de) Verfahren zur herstellung von calciumzusammensetzungen im kontinuierlichen fliessbett
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
DE602005011814D1 (de) Verfahren zur herstellung von enantiomerreinen 1,1'-spirobiindan-6,6'-diol-derivaten
DE60205676D1 (de) Verfahren zur Herstellung eines Gegenstandes
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t
DE602004030603D1 (de) Verfahren zur herstellung gamma-carboxylierter proteine
ATE440605T1 (de) Verfahren zur herstellung von camptothecin- derivaten
ATE374755T1 (de) Verfahren zur herstellung von 1,3,5- triazincarbamaten und -harnstoffen
DE602005026841D1 (de) Verfahren zur herstellung von 1,2,2,2-tetrafluor-ethyl-difluor-methylether
ATE513840T1 (de) Verfahren zur herstellung optisch aktiver diphosphane